Recon: Kerfuffle over WHO's Wuhan mission; BMS inks $1.3 B cancer deal

• New, Daily Coronavirus Cases Drop Below 100K For First Time In Months (NPR)
• U.S. Continues To Accelerate Vaccination Strategy (NPR)
• Seven coronavirus variants potentially similar to UK type have been detected in US: study (The Hill) (NYT)
• Fauci Awarded $1 Million Israeli Prize For 'Speaking Truth To Power' Amid Pandemic (NPR)
• Pentagon approves 20 additional COVID-19 vaccination teams (The Hill)
• Three Men Are Accused in Scheme to Sell Covid-19 Vaccines (NYT) (DOJ)
• COVID-19 leads to explosion in cyberattacks, data breaches (MedTech Dive)
• Four potential COVID-19 therapeutics enter Phase 2/3 testing in NIH ACTIV-2 trial (NIH)
• What Life Sci Attys Think Of Biden's Pace Choosing FDA Boss (Law360)

• WHO Wuhan probe finds signs original outbreak more widespread than previously thought: report (The Hill) (Reuters)
• 'Politics was always in the room.' WHO mission chief reflects on China trip seeking COVID-19’s origin (Science)
• U.S. 'gravely damaged' coronavirus cooperation, China says as feud erupts over WHO probe (NBC)
• Can Covax deliver the vaccines much of the world needs? (Financial Times)
• You Think The U.S. Has Vaccine Issues? 130 Countries Haven't Even Started Vaccinating (NPR)
• Pan-European consortium seeks big pharma partner for COVID-19 shot (Reuters)
• Ebola vaccination campaign begins in Democratic Republic of Congo (Reuters)
• Israeli study finds 94% drop in symptomatic COVID-19 cases with Pfizer vaccine (Pharmafile) (Reuters)
• February Pharmacovigilance Risk Assessment Committee (PRAC) meeting highlights (European Pharmaceutical Review)
• Norwegian language requirement will apply following MDR implementation (Emergo)
• India may approve Russia's Sputnik V vaccine within next few weeks: Report (Economic Times)
• COVID-19 vaccines touch down in Australia, New Zealand, inoculations to start (Reuters)

• Protecting the Most Vulnerable by Vaccinating the Most Active (RAND)
• Pfizer exec 'confident' in ability to deliver 2 billion coronavirus vaccine doses this year (The Hill)
• Can Pfizer and Moderna End the Pandemic by Sharing Their Vaccine Designs? It’s Not that Simple (KHN)
• Half Doses of Moderna Produce Neutralizing Antibodies (Marginal Revolution)
• One dose of COVID-19 vaccine provokes strong immune response in those previously infected (PharmaNews)
• AZ/Oxford to trial COVID-19 vaccine in children (BioPharma Reporter)
• U.K. Covid Variant Is Likely 30-70% Deadlier, New Research Finds (Forbes)
• A machine-learning approach to finding treatment options for Covid-19 (MIT)
• Researchers propose that humidity from masks may lessen severity of COVID-19 (NIH)
• From A to Z, Supplements Fail for COVID-19 (MedPage Today)

• EU Fast-Track Fail For Another BMS CAR-T Cell Therapy (Pink Sheet)
• A gene therapy pipeline takes shape for a cluster of rare diseases (BioPharma Dive)
• Recombinant Zoster Vaccine (Shingrix) real-world effectiveness in the first two years post-licensure (PubMed)
• NICE rejects Lilly’s Verzenios for advanced breast cancer (PharmaTimes)
• Therapeutic proteins and oral vaccines market to surpass $300,000 million by 2027 (European Pharmaceutical Review)
• Molecular Templates signs cancer deal with BMS worth up to $1.3bn (Pharmafile)
• Novel ionic liquid enables uniform chemotherapy delivery in solid tumours (European Pharmaceutical Review)
• FDA Grants Rare Pediatric Disease and Orphan Drug Designations to Rescindo’s Treatment for Kabuki Syndrome (Rare Daily)
• New Drug OK'd for Chemo-Induced Myelosuppression in SCLC (MedPage Today)

• Precision medicine in human heart modeling : Perspectives, challenges, and opportunities (PubMed)
• Home testing for COVID-19: Benefits and limitations (PubMed)
• How is the FDA maintaining digital health safety standards? (PharmaLetter)
• Longeviti CEO Talks Neurosurgical Implants and COVID-19 (MD+DI)
• Blockchain could accelerate drug development: Bloqcube (Outsourcing Pharma)
• Dexcom launches first VC fund (MedCity News)
• STAT-Harris Poll: 1 in 4 Americans were unable to get a Covid-19 test when they wanted one (STAT)

• Against Regulatory Nationalism (Marginal Revolution)
• Congressional Democrats File Amicus Brief in ACOG v. FDA (Dianne Feinstein)
• Walgreens Revealed As Investor In Subsidiary Of Health Insurance Company Under Federal Investigation (Forbes)
• Zantac Chronicles – No Innovative, or Innovator, Liability (Drug and Device Law Blog)
• The Toolgen Interference: Broad Preliminary Motions List (Patent Docs)
• 7 False Claims Act Enforcement Trends To Watch (Law360)
• US appeals court confirms Amgen's patent claims on PCSK9 antibodies invalid (PharmaLetter)